ClinicalTrialsFinder

Biopsy Procedure Clinical Trials

100 recruitingProcedure
Phase 262Phase 143Phase 35Not Applicable2Early Phase 12

Showing 1–20 of 100 trials

Recruiting
Phase 1Phase 2

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

Malignant Glioma
National Cancer Institute (NCI)132 enrolled127 locationsNCT05099003
Recruiting
Phase 2

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

Stage IV Nasopharyngeal Carcinoma AJCC v8Stage III Nasopharyngeal Carcinoma AJCC v8Stage II Nasopharyngeal Carcinoma AJCC v8
National Cancer Institute (NCI)50 enrolled85 locationsNCT06064097
Recruiting
Phase 1

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+13 more
National Cancer Institute (NCI)36 enrolled2 locationsNCT07137416
Recruiting
Phase 2

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Metastatic Malignant Solid NeoplasmAdvanced Malignant Solid Neoplasm
National Cancer Institute (NCI)500 enrolled27 locationsNCT06311214
Recruiting
Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting
Phase 2

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Acute Myeloid LeukemiaMyelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+2 more
National Cancer Institute (NCI)2,000 enrolled347 locationsNCT05564390
Recruiting

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

Pancreatic Neoplasm
ECOG-ACRIN Cancer Research Group770 enrolled424 locationsNCT04239573
Recruiting
Phase 2

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Recurrent Ovarian CarcinomaRecurrent Endometrial CarcinomaRecurrent Fallopian Tube Carcinoma+1 more
National Cancer Institute (NCI)165 enrolled296 locationsNCT05554328
Recruiting
Phase 2

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

Sinonasal Squamous Cell CarcinomaStage III Sinonasal Cancer AJCC v8Stage IVA Sinonasal Cancer AJCC v8+1 more
National Cancer Institute (NCI)108 enrolled2 locationsNCT07281417
Recruiting
Phase 1Phase 2

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

Stage IV Lung Cancer AJCC v8Extensive Stage Lung Small Cell Carcinoma
National Cancer Institute (NCI)45 enrolled43 locationsNCT06287775
Recruiting
Phase 1

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

Recurrent Ovarian High Grade Serous AdenocarcinomaRecurrent Platinum-Resistant Ovarian Carcinoma
National Cancer Institute (NCI)42 enrolled27 locationsNCT04633239
Recruiting
Phase 2

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

Resectable Intrahepatic Cholangiocarcinoma
National Cancer Institute (NCI)27 enrolled58 locationsNCT06050252
Recruiting
Phase 1Phase 2

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8Locally Advanced Pancreatic Adenocarcinoma
National Cancer Institute (NCI)92 enrolled44 locationsNCT04172532
Recruiting
Not Applicable

Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer

Prostate AdenocarcinomaStage II Prostate Cancer AJCC v8Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Jonsson Comprehensive Cancer Center45 enrolled1 locationNCT07468903
Recruiting
Phase 1

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmPlatinum-Resistant Ovarian High Grade Serous Adenocarcinoma
National Cancer Institute (NCI)55 enrolled7 locationsNCT04585958
Recruiting
Phase 2

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Head and Neck Squamous Cell Carcinoma+22 more
National Cancer Institute (NCI)150 enrolled222 locationsNCT05136196
Recruiting
Phase 2

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8
University of Washington25 enrolled1 locationNCT04329065
Recruiting
Phase 1

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

Locally Advanced Head and Neck Squamous Cell CarcinomaClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Stage III Hypopharyngeal Carcinoma AJCC v8+23 more
National Cancer Institute (NCI)46 enrolled18 locationsNCT05172245
Recruiting
Phase 1

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

Metastatic SarcomaMetastatic LeiomyosarcomaUnresectable Leiomyosarcoma+9 more
National Cancer Institute (NCI)30 enrolled16 locationsNCT05711615
Recruiting
Phase 2

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+28 more
National Cancer Institute (NCI)36 enrolled4 locationsNCT04550494